Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 116

Therapies Virus DNA Clinical Trials 116

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. All tested negative for the virus but live with someone who has COVID-19.

Treatment 52

Treatment Trials Hospitals Virus 52

The Pharma Data

APRIL 8, 2022

Using a Human Lung Chip that replicates the structures and functions of the lung air sac, or “alveolus,” the research team discovered that applying mechanical forces that mimic breathing motions suppresses influenza virus replication by activating protective innate immune responses. During his Ph.D.

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Hospitals 52

Hospitals Trials International Clinical Trials 52

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 85

RNA Virus DNA Vaccine 85

Codon

JANUARY 21, 2024

Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October. But for all of their benefits, human challenge trials have their drawbacks. Jake himself has participated in both Zika and Shigella challenge trials.

Vaccine 109

Vaccine Trials Disease Treatment 109

The Pharma Data

DECEMBER 23, 2020

23, 2020 — Because COVID-19 is known to raise the odds for dangerous blood clots, blood thinners have quickly become part of routine care for many hospitalized patients. The three trials are being conducted on four continents. WEDNESDAY, Dec. “Such abnormal bleeding could be lethal if not quickly diagnosed and treated.”

Trials 52

Trials Hospitals Clinical Trials Doctors 52

The Pharma Data

APRIL 27, 2023

RSV causes over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in adults aged 60 years and older each year in Europe. The positive opinion is supported by data from the pivotal AReSVi-006 ( A dult R espiratory S yncytial V irus) phase III vaccine efficacy trial. Source link: [link]

Virus 40

Virus Vaccine Trials Clinical Trials 40

The Pharma Data

MARCH 3, 2022

Pfizer will publish outcomes from this clinical trial at a future date. If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Pfizer Inc. 8,9 For older adults in the U.S.,

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Virus 52

The Pharma Data

SEPTEMBER 1, 2020

Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after the data proved inconclusive. The Phase 3 trial did not meet the primary or secondary endpoints compared with placebo and established hospital care. Conor Kavanagh. Source link.

Trials 52

Trials Treatment Clinical Trials Vaccine 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The trial on 10,000 people will now see if the vaccine can prevent people getting ill.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

SEPTEMBER 2, 2021

The Phase 3 RENOIR trial of RSVpreF is a global, randomized, double-blind, placebo-controlled study that expects to enroll approximately 30,000 participants 60 years and older. Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness. Burden of RSV. 2 In the U.S.,

Clinical Trials 52

Clinical Trials Trials Vaccine Virus 52

The Pharma Data

JANUARY 18, 2021

The first patient is expected to be enrolled in this trial in the upcoming weeks. BT-001 IS AN ONCOLYTIC VIRUS GENERATED WITH TRANSGENE’S INNOVATIVE INVIR.IO oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T

Virus 40

Virus Trials Clinical Trials Engineering 40

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 3, 2020

Another record-breaking day of COVID-19 hospitalizations and deaths underscored Redfield’s grim warning. The number of people hospitalized for COVID-19 on Wednesday passed 100,000, nearly double the highest point seen last spring. With hospitals filling up in multiple states, the days ahead do appear bleak.

Hospitals 52

Hospitals Vaccine Long-Term Care Facilities Nurses 52

The Pharma Data

MAY 16, 2022

million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths. The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics.

Vaccine 52

Vaccine Hospitals Virus Disease 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 26, 2021

“The death toll from COVID-19 continues to rise around the world and hospitalizations, particularly in the U.S., These data further support our belief that bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and death in high-risk COVID-19 patients.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

JUNE 2, 2022

Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19. Bristol Myers Squibb (NYSE: BMY) today announced topline results from the Phase 3 Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-1) Immune Modulators clinical trial, sponsored by the National Institutes of Health (NIH).

Hospitals 52

Hospitals Treatment Clinical Trials Disease 52

The Pharma Data

AUGUST 7, 2020

The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinical trials in the future. In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

JANUARY 13, 2021

patients hospitalized with COVID-19. Ensifentrine has been well tolerated in clinical trials involving more than 1,300 people. Patient Population: 45 hospitalized patients with COVID-19. Primary Endpoint: Proportion of patients recovered from COVID-19 and no longer hospitalized at Day 29.

Hospitals 52

Hospitals Clinical Trials Therapies Treatment 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Treatment Hospitals 52

The Pharma Data

MARCH 11, 2021

This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The full results of the trial will be submitted for publication in a peer-reviewed journal later this year.

Trials 52

Trials Hospitals Treatment Science 52

The Pharma Data

JUNE 7, 2023

RSV is a common, contagious respiratory virus that leads to over 270,000 hospitalisations and approximately 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe. The authorisation is based on GSK’s landmark positive pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial data.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

MARCH 23, 2021

(NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.

Virus 52

Virus Vaccine Hospitals Pharmacokinetics 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. It works to block the “spike protein” in the virus before it can enter human cells and cause illness. TAMPA, Fla., For more information, visit health.usf.edu.

Hospitals 40

Hospitals Treatment Virus Nurses 40

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

The first indication that those hopes might be realized came from the announcement just a month ago of a 50 percent reduction in hospitalizations from the Merck and Ridgeback drug molnupiravir (originally developed with an NIH grant to Emory University, Atlanta). But would it work to treat COVID-19 in an infected person?

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. Cutting through the usual red tape and working with an intense sense of purpose, the partnership took a mere matter of weeks to set up its first four clinical trials. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

JANUARY 26, 2021

Eli Lilly expanded its ongoing BLAZE-4 study to include Vir’s monoclonal antibody in the trial. Data published last week showed that bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial. . Food and Drug Administration to treat mild-to-moderate COVID-19 patients.

Virus 52

Virus Trials Nurses Research Laboratories 52

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine. James Miessler.

Vaccine 52

Vaccine Virus Research Laboratories Trials 52

Codon

SEPTEMBER 29, 2024

The average pass rate of phase I trials went up by 5 percent. Their pipelines were bursting with promising candidates, and their success rates in clinical trials were astronomical compared to the industry standard of just a few years back. A flurry of new, promising therapeutic targets arose.

Engineering 131

Engineering Virus DNA Therapies 131

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. The full set of results will be published once the complete Phase 1/2a trial data are available.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52